Every Form 4 that Zivo Bioscience Inc (ZIVO) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow ZIVO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ZIVO filings page.
Zivo Bioscience, Inc. reported that an entity associated with 10% owner Mark E. Strome acquired additional common stock. On April 17, 2026, Strome Mezzanine Fund II, LP purchased 100,000 shares of Zivo common stock at $2.00 per share.
Following this transaction, the reporting group’s indirect holdings rose to 572,942 shares of common stock. The filing notes that the reporting persons may be deemed to share voting and investment power over these shares, while also disclaiming beneficial ownership for certain legal purposes.
Zivo Bioscience director and 10% owner–associated entity buys shares. An entity associated with director and ten percent owner Laith L. Yaldoo, identified as HEP Investment, LLC, made an open-market purchase of 1,543 shares of Zivo Bioscience common stock at $9.72 per share. After this transaction, the filing reports 583,615 shares of common stock indirectly owned.
Zivo Bioscience reported that investment entities associated with 10% owner Mark E. Strome, through Strome Mezzanine Fund II, LP, bought 20,000 shares of common stock at $9.77 per share and 2,000 common stock purchase warrants on February 12, 2026.
After these indirect purchases, the entities reported beneficial ownership of 472,942 common shares and 45,071 warrants.
Zivo Bioscience insider reporting shows an indirect open-market purchase of common stock tied to director and 10% owner Laith L. Yaldoo. On 02/10/2026, HEP Investments LLC, an entity associated with Yaldoo, bought 2,434 shares of Zivo Bioscience common stock at $10.27 per share. Following this transaction, HEP Investments LLC indirectly held 582,072 shares of common stock.
Zivo Bioscience director Alison Cornell reported buying additional company stock. On January 26, 2026, she purchased 11,709 shares of common stock at a price of $8.54 per share. Following this transaction, she directly beneficially owns 279,481 shares of Zivo Bioscience common stock.
Zivo Bioscience, Inc. President and CEO John B. Payne reported an open-market purchase of company stock. On 01/26/2026, he bought 11,709 shares of common stock at $8.54 per share. Following this transaction, he directly owns 19,618 shares of Zivo Bioscience common stock.
Zivo Bioscience director and 10% owner Christopher D. Maggiore reported a small open-market purchase of common stock. On 01/14/2026, he bought 1,766 shares of Zivo Bioscience common stock at a price of $8.49 per share, coded as a purchase transaction.
Following this trade, Maggiore beneficially owned 519,292 shares of Zivo Bioscience common stock in direct ownership form, indicating his stake as both a director and a more than 10% shareholder.
Zivo Bioscience director and 10% owner–associated entity acquires additional shares. On January 14, 2026, an entity associated with Laith L. Yaldoo, HEP Investments LLC, purchased 1,766 shares of Zivo Bioscience common stock at $8.49 per share in an open-market transaction.
Following this purchase, HEP Investments LLC indirectly holds 579,638 shares of Zivo Bioscience common stock attributed to Yaldoo’s beneficial ownership.
Zivo Bioscience, Inc. director and 10% owner reported buying additional company shares. On 11/28/2025, an indirect account, HEP Investments LLC, purchased 2,777 shares of Zivo Bioscience common stock at a price of $9 per share. After this transaction, the reporting person beneficially owned 577,872 shares of common stock indirectly through HEP Investments LLC.
Zivo Bioscience (ZIVO): Insider transaction reported. Affiliates of Strome Group reported a purchase of Zivo Bioscience common stock and warrants on 10/13/2025. The filing shows a purchase of 20,259 shares of common stock at $12.34 per share, held indirectly by an entity.
The report also lists acquisition of 2,025 Common Stock Purchase Warrants with an exercise price of $12.34, exercisable on 10/13/2025 and expiring on 10/12/2030. Following these transactions, the filing shows 452,942 common shares and 43,071 derivative securities beneficially owned indirectly by the reporting entity. The securities were acquired pursuant to a Securities Purchase Agreement.
Zivo Bioscience (ZIVO) reported an insider purchase. Director and 10% owner Laith L. Yaldoo acquired 1,659 shares of common stock on 10/10/2025 at $12.05 per share, held indirectly through HEP Investments LLC. Following the trade, beneficial ownership was 575,095 shares, reported as indirect.
Christopher D. Maggiore, a director and reported >10% owner of Zivo Bioscience, Inc. (ZIVO), purchased 23,682 shares of the companys common stock on 10/08/2025 at a price of $12.01 per share. After this transaction the filing reports aggregate beneficial ownership of 517,526 shares, which corrects a prior overstatement caused by an administrative error that had overstated ownership by 13,156 shares. The transaction is reported on a Form 4 and was signed by the reporting person on 10/09/2025. The filing shows the acquisition coded as P and lists the ownership form as Direct.
Zivo Bioscience (ZIVO) reported an insider equity award. On 10/02/2025, a reporting person who is a Director and 10% Owner received 926 nonstatutory stock options to buy common stock at an exercise price of $12.03 per share, expiring on 10/02/2035. The filing notes the option grant was issued under the 2024 Equity Incentive Plan for Non-Employee Directors in lieu of retainer fees totaling $9,452.05. Ownership of these derivative securities is listed as Direct (D).
Zivo Bioscience, Inc. (ZIVO) director and 10% owner Christopher D. Maggiore was granted 1,075 nonstatutory stock options on 10/02/2025 under the 2024 Equity Incentive Plan for Non-Employee Directors in lieu of retainer fees of $10,964.38. The options have an exercise price of $12.03, are exercisable immediately on 10/02/2025, and expire on 10/02/2035. The filing shows the underlying common stock amount as 1,075 shares and reports the transaction on a Form 4 signed 10/06/2025. This is a routine director compensation award recorded as equity rather than cash.
Zivo Bioscience, Inc. (ZIVO) director Alison Cornell received a grant of 1,223 nonstatutory stock options on 10/02/2025 under the 2024 Equity Incentive Plan for Non-Employee Directors in lieu of retainer fees totaling $12,476.71. The options have an exercise price of $12.03, are exercisable immediately on 10/02/2025, and expire on 10/02/2035
This transaction increases the reporting person’s direct beneficial ownership by 1,223 underlying shares. The filing is a routine director compensation disclosure showing equity issued instead of cash fees to align compensation with shareholder interests.
Laith Yaldoo, a director and 10% owner of Zivo Bioscience, Inc. (ZIVO), reported a purchase of 15,322 shares of the company's common stock on 09/30/2025 at a price of $15.99 per share. After the transaction, the filing shows beneficial ownership of 573,436 shares held indirectly through HEP Investments LLC. The Form 4 was signed on 10/02/2025.
This report documents an insider acquisition, increasing the reporting person's indirect stake via an investment vehicle. The filing does not disclose any derivative transactions or additional context for the purchase beyond the amounts, price, and ownership form.